14 Feb 2012
HOME
Pharma/CDC on Brain damage from vaccines, Fauci, Phages, Bioweapons manufacture
HHS.gov is Incompetent; BMJ calls fraud "crime.")
Official: CFIDS and MS-Lyme are the
same disease; Epstein-Barr
ELISA = arbitrary cutoff.
Disclaimer
1998, CIA Oilmen & Israelis plan to overthrow Saddam for the oil.
Bush/Gore Oil/War-(Oct,2000)
Bush's own explainer (Oct
2000):
Iraq Oil
Iraq was an oil-theft war.
Besides the obvious: PubMed ID 9394822 "None of the mice previously immunized with OspA peptides were protected against experimental infection, in spite of the appearance of protective antibodies."
rOSPA WAS NOT A VACCINE
1) Yale did not demonstrate that there were not spirochetes in the ticks:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1608951&dopt=Abstract
Elimination of
Borrelia burgdorferi from vector ticks
feeding on OspA-immunized mice.
Fikrig E, Telford SR 3rd, Barthold
SW, Kantor FS, Spielman A, Flavell RA.
Proc Natl Acad Sci U S A. 1992 Jun
15;89(12):5418-21.
2) To assess outcomes, use chromosomally and not plasmid-coded DNA:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8234271&dopt=Abstract
Borrelia
burgdorferi is clonal: implications for
taxonomy and vaccine development.
Dykhuizen DE, Polin DS, Dunn JJ,
Wilske B, Preac-Mursic V, Dattwyler RJ,
Luft BJ.
Proc Natl Acad Sci U S A. 1993 Nov
1;90(21):10163-7.
3) rOspA vaccination results in escape mutants or variants spirochetes which INCREASE at a greater rate than normal.
Selection of
variant Borrelia burgdorferi isolates
from mice immunized with outer surface
protein A or B.
Fikrig E, Tao H, Barthold SW, Flavell
RA.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7729870&dopt=Abstract
4) Experiments in vitro in which complement is added demonstrate the antibodies to rOspA alone do not kill the spirochetes:
Borrelia
burgdorferi escape mutants that survive
in the presence of antiserum to the OspA
vaccine are killed when complement is
also present.
Sole M, Bantar C, Indest K, Gu Y,
Ramamoorthy R, Coughlin R, Philipp MT.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9596714&dopt=Abstract
5) OspA vaccination was not demonstrated to protect monkeys from infection:
The outer surface
protein A (OspA) vaccine against Lyme
disease: efficacy in the rhesus monkey.
Philipp MT, Lobet Y, Bohm RP Jr,
Roberts ED, Dennis VA, Gu Y, Lowrie RC
Jr, Desmons P, Duray PH, England JD,
Hauser P, Piesman J, Xu K.
Vaccine. 1997 Dec;15(17-18):1872-87.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9413097&dopt=Abstract
6) rOspA vaccination did not protect rabbits:
Comparison of
protection in rabbits against
host-adapted and cultivated Borrelia
burgdorferi following infection-derived
immunity or immunization with outer
membrane vesicles or outer surface
protein A.
Shang ES, Champion CI, Wu XY, Skare
JT, Blanco DR, Miller JN, Lovett MA.
Department of Microbiology and
Immunology, Department of Medicine,
School of Medicine, University of
California, Los Angeles, California
90095, USA.
"Analysis of the antibody responses to outer membrane proteins, including DbpA, OspA, and OspC, suggests that the remarkable protection exhibited by the infection-immune rabbits is due to antibodies directed at antigens unique to or markedly up-regulated in host-adapted B. burgdorferi."
Natural infection was better in infection-immune rabbits, because of adaptation to antigenic variation.
7) OspA was not shown to protect mice, and why, by Russell Johnson:
Resistance to
tick-borne spirochete challenge induced
by Borrelia burgdorferi strains that
differ in expression of outer surface
proteins.
Kurtti TJ, Munderloh UG, Hughes CA,
Engstrom SM, Johnson RC.
Infect Immun. 1996 Oct;64(10):4148-53
There was no reduction of strain 297 spirochetes in ticks that fed on four hamsters immunized with M297, but the hamsters were protected.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8926082&dopt=Abstract
The journal publications of Russell Johnson--> MEDLINE: "Johnson RC [au] and spirochete"
8) Other lipoprotein vaccine failures and activation of latent infection:
The 19-kD antigen
and protective immunity in a murine
model of tuberculosis.
Yeremeev VV, Lyadova IV, Nikonenko
BV, Apt AS, Abou-Zeid C, Inwald J, Young
DB.
"These results are consistent with a model in which the presence of the 19-kD protein has a detrimental effect on the efficacy of vaccination with live mycobacteria."
Mycobacterium
tuberculosis 19-kilodalton lipoprotein
inhibits Mycobacterium smegmatis-induced
cytokine production by human macrophages
in vitro.
Post FA, Manca C, Neyrolles O, Ryffel
B, Young DB, Kaplan G.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11179309&dopt=Abstract
The
19-kDa lipoprotein of M. tuberculosis,
expressed in M. vaccae or M. smegmatis
(M. smeg19kDa), abrogates this
protective immunity....Thus, the
immunosuppressive effect is dependent on
glycosylated and acylated 19-kDa
lipoprotein present in the phagosome
containing the mycobacterium. These
results suggest that the diminished
protection against challenge with M.
tuberculosis seen in mice vaccinated
with M. smegmatis expressing the 19-kDa
lipoprotein is the result of reduced TNF-alpha
and IL-12 production, possibly leading
to reduced induction of T-cell
activation.
RELATED:
Benach and Radolf → Extremely high titers of OspA- antibody are necessary to be protective
POST LYMErix SYNDROME
Vaccination with lipoprotein vaccines exacerbate infection and make the disease undetectable.
The evidence from the vaccine trial and adverse events reported afterwards, suggests rOspA activates latent infections.
OspA is biologically active in the free form (1).
OspA binds Plasminogen, an enzyme which degrades membranes
OspA induces the expression of the anti-inflammatory cytokine IL-10 (2) (causes immune suppression)
Borreliosis, itself, is associated with activation of Epstein-Barr virus (3).
Epstein-Barr virus is associated with B cell changes. Borreliosis is associated with B cell changes. (Dorward, Spleens )
Giving asymptomatically infected Borreliosis patients the vaccine therefore appears to have created a disaster, not the least of which is new neoplasms, not reported in this abstract, and likely not reported to the World Health Organization, because Yale wrote that they scewed the results to fit into WHO's adverse events listing.
Mycoplasmal lipoprotein vaccine have failed to protect, in Tuberculosis. The lipoproteins seem to be related to fungi (that is, they are identical). Indeed, the mycobacterial lipoproteins of 19 and 35 kD tried as vaccine in tuberculosis seem to have the same negative effects as OspA
"Thus, the immunosuppressive effect is dependent on glycosylated and acylated 19-kDa lipoprotein present in the phagosome containing the mycobacterium. These results suggest that the diminished protection against challenge with M. tuberculosis seen in mice vaccinated with M. smegmatis expressing the 19-kDa lipoprotein is the result of reduced TNF-alpha and IL-12 production, possibly leading to reduced induction of T-cell activation."
=========
OspA and IL-10: MEDLINE
ActionLyme, 2001, Vaccine Presentation of Empirical Results, and that OspA was not a vaccine. It was not qualified with a valid standard http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf
Pam Weintraub: http://www.whale.to/m/lymerix8.html
LYME FOUNDATION Re LymeRIX
LYME ASSOCIATION Re: LymeRIX
==============================
1) Binds a human degradive enzyme plasminogen and is active in the free form:
Infection 1996 Mar-Apr;24(2):190-4
The
outer surface protein A (OspA) of
Borrelia burgdorferi: a vaccine
candidate and bioactive mediator.
Kramer MD, Wallich R, Simon MM.
Institut fur Immunologie, Universitat
Heidelberg, Germany.
In the search for a suitable vaccine
candidate for Lyme borreliosis the
principles of protective immunity were
studied in a murine model of Borrelia
burgdorferi infection. It was found that
the spirochetal outer surface protein A
(lipOspA) in its native and recombinant
lipidated form induces monospecific
immune sera, which in passive transfer
experiments protect SCID mice against
experimental and tick-borne infection
and disease. These and similar findings
of independent groups led to the
development of a vaccine formulation
containing lipOspA. When tested in
clinical phase I/II safety trials the
recombinant lipOspA vaccine was shown to
be safe, immunogenic and able to elicit
borreliacidal antibodies. At present,
clinical phase III efficacy trials are
being conducted. B. burgdorferi
infection involves the dissemination of
the spirochetes from the site of the
tick bite, infection of distant organs,
and induction of a chronic inflammatory
process. Recent studies indicate that
the spirochetes may utilize host-derived
enzyme systems to increase their
virulence/pathogenicity. It was found
that lipOspA serves as a surface
receptor for the host-derived
proteolytic enzyme plasmin(ogen), the
central component of the so-called
plasminogen activator system. Moreover,
it was found that spirochetes are able
to activate endothelial cells and
blood-derived leukocytes, such as
monocytes/macrophages, B cells and T
cells, to express functions and/or
secrete molecules, which are known to
promote inflammatory responses. Part
of these activities were exerted by the
isolated lipOspA. The studies
indicate an important role of lipOspA,
both for the induction of a protective
immune response by the host, as well as
for the pathogenic processes elicited
during B. burgdorferi infection.
PMID: 8740121 [PubMed - indexed for
MEDLINE]
Which means, who knows what's happening to people who receive this as vaccination if this mechanism is at work.
2) Induces the antiiflammatory cytokine IL-10 (suppresses the immune response).
People with Lyme borreliosis often test positive to Epstein-Barr. That is, IgM to Epstein-Barr apparently "cross-reacts" with Borrelia burgdorferi OspC. That is, people who are infected with Borrelia, and who are "treated" to the CDC's Dearborn serodiagnostic criteria, and therefore told they have Chronic Fatigue Syndrome (Chronic Epstein-Barr), may have also activation of latent Epstein-Barr, as described here:
Interaction of Borrelia burgdorferi
sensu lato with Epstein-Barr virus in
lymphoblastoid cells.
Hulinska D, Roubalova K, Schramlova
J.
National Reference Laboratory on
Borreliosis, Electron Microscopy,
National Institute of Public Health,
Prague, Czech Republic.
Since the possibility of interruption of
latent EBV infection has been suggested
by the induction of the lytic virus
cycle with chemical substances, other
viruses, and by immunosuppression, we
hypothesized that the same effect might
happen in B. burgdorferi sensu lato
infection as happens in Lyme disease
patients with positive serology for both
agents. We have observed EBV replication
in lymphoblastoid cells after
superinfection with B. garinii and B.
afzelii strains after 1 and 4 h of their
interaction. We found that viral and
borrelial antigens persisted in the
lymphoblasts for 3 and 4 days.
Morphological and functional
transformation of both agents facilitate
their transfer to daughter cells.
Association with lymphoblasts and
internalization of B. garinii by tube
phagocytosis increased replication of
viruses more successfully than B.
afzelii and chemical inductors.
Demonstration of such findings must be
interpreted cautiously, but may prove a
mixed borrelial and viral cause of
severe neurological disease.
PMID: 12630667 [PubMed - in process]
3) "Blot-smudging" The question that arises is, if OspA is "sticky" (according to an Alan Barbour patent), how can we be sure free OspA molecules are the actual immunogen a person is injected with, if the outcome, in antibodies, is as below? It appears that clumps of OspA of various sizes are being injected into people. And if OspA is the reactive molecule it is claimed to be, how do we know it is not causing Immune complex vasculitis?, as part of the Post-LYMErix Syndrome?
This same thing occurred in the Monkey trials of rOspA. It was not reported that this problem was addressed.
http://www.journals.uchicago.edu/CID/journal/issues/v31n1/991200/991200.html
Figure 1. Results of
Western blotting (MarBlot for
detection of IgG antibody
to Borrelia burgdorferi;
MarDx, Carlsbad, CA) of
serum specimens from 14
recipients of the
recombinant outer surface
protein A Lyme disease
vaccine. Representative molecular
weights (in kDa) are
identified in the far
left column. P, a
positive control subject
with PCR analysis positive
Lyme arthritis; N,
a negative control subject.
Study subjects 110: A,
baseline; B, 30 days
after dose 3. Study
subjects 1114: A, baseline;
C, 30 days after
dose 2; D, 8 months
after dose 3; E,
24 months after dose
3.
|
Clinical
Infectious Diseases 2000;31:42-47
© 2000 by the Infectious Diseases
Society of America. All rights reserved.
1058-4838/2000/3101-0010$03.00
Detection of Multiple Reactive Protein Species by Immunoblotting after Recombinant Outer Surface Protein A Lyme Disease Vaccination
Philip J. Molloy,1,2 Victor P. Berardi,2 David H. Persing,2,3,a and Leonard H. Sigall4
1Rheumatology Associates of Southeastern Massachusetts, Plymouth, and 2IMUGEN, Norwood, Massachusetts; 3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; and 4Division of Rheumatology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick
Received 31 August 1999; revised 3 December 1999; electronically published 17 July 2000.
| Laboratory confirmation of
the diagnosis of Lyme
disease is based on the
detection of an immune
response to Borrelia
burgdorferi. The
serodiagnosis of B. burgdorferi
infection is complex and
may be further confounded
by the immune response to
the recombinant outer surface
protein A (OspA) Lyme
disease vaccine. To describe
how the serological response
to the recombinant OspA
Lyme disease vaccine affects
testing for antibody to
B. burgdorferi, 240
specimens from 80 study
subjects were obtained at
defined intervals after
recombinant OspA Lyme
disease vaccination. Samples were
tested by indirect
enzyme-linked
immunosorbent assay (ELISA),
antibody capture enzyme
immunoassay (EIA), and
Western blotting (WB).
After recombinant OspA Lyme
disease vaccination, ELISA for
98% of the study
subjects revealed reactivity. WB
with use of OspA-containing
B. burgdorferi strains
as sources of antigens
demonstrated multiple
bands. Results of testing
with a US Food and Drug
Administrationapproved WB
kit showed homogeneous reactivity
in the molecular weight
region >30 kDa. Testing
with OspA-free strains
completely eliminated all
vaccine-associated reactivity
by both antibody capture
EIA and WB.
|
For collection
of serum samples, there
was separate institutional review
board approval, and informed
consent was obtained from
the study subjects.
Guidelines for human
experimentation of the US
Department of Health and
Human Services and/or those
of the authors' institutions
were followed in the conduct
of the clinical research.
a
Current affiliation: Corixa
Corporation Infectious Disease Research
Institute, Seattle Life Sciences
Center, Seattle, WA.
Reprints or
correspondence: Victor
Berardi, IMUGEN,
220 Norwood
Park South,
Norwood, MA 02062
(vberardi@imugen.com).